Author

W.-J. Jiang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:deep learning· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

H.-J. Wu· 2 shared L. Yu· 2 shared T. Fei· 2 shared X. Wang· 2 shared Y. Yao· 2 shared Z. Li· 2 shared C. Zhong· 1 shared D. Xu· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H.-J. Wu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer

C. Zhong, W.-J. Jiang, Y. Yao, Z. Li, Y. Li, S. Wang, X. Wang, W. Zhu, S. Wu, J. Wang, S. Fan, S. Ma, Y. Liu, H. Zhang, W. Zhao, , T. Fei

This study identifies convergent therapeutic targets for chemoresistance in cancer using CRISPR screens across multiple drug conditions and cancer models.

bioRxiv · Apr 24, 2024Cancer Biology

A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism

Y. Yao, Y. Zhang, Z. Li, Z. Chen, X. Wang, Z. Li, L. Yu, X. Cheng, W. Li, W.-J. Jiang, H.-J. Wu, Z. Feng, J. Sun, T. Fei

This study uses deep learning to screen FDA-approved drugs and TCM compounds for anti-SARS-CoV-2 activity by targeting cell entry, identifying several effective candidates.

bioRxiv · Jun 3, 2023Microbiology